Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 7/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040906 | 0.89 | NPC1 (0.46) | NPC1RAB9ANOS2CD38MAPT | |
| SCHEMBL5036523 | 0.88 | NPC1 (0.48) | NPC1RAB9ANOS2CD38MAPT | |
| SCHEMBL5037996 | 0.87 | NPC1 (0.44) | NPC1RAB9ANOS2CD38MAPT | |
| SCHEMBL5043085 | 0.87 | NPC1 (0.41) | NPC1RAB9ACD38LIPGMMP1 | |
| SCHEMBL5036222 | 0.87 | LMNA (0.38) | NOS2CD38MAPTHTTMMP1 | |
| SCHEMBL5043014 | 0.87 | ENPP3 (0.39) | NPC1RAB9AMAPTHTT | |
| SCHEMBL7050284 | 0.86 | MET (0.36) | CD38ROCK2MAPTHTTMMP1 | |
| SCHEMBL7176912 | 0.86 | MAPT (0.39) | NPC1RAB9AROCK2MAPTHTT | |
| SCHEMBL7049236 | 0.86 | MMP1 (0.38) | NPC1RAB9ANOS2ROCK2MAPT | |
| SCHEMBL5033770 | 0.85 | CD38 (0.41) | NPC1RAB9ACD38LIPGMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |